Show simple item record

dc.contributor.authorFeruglio, Sirien_US
dc.contributor.authorTrøseid, Mariusen_US
dc.contributor.authorDamås, Jan Kristianen_US
dc.contributor.authorKvale, Dagen_US
dc.contributor.authorDyrhol-Riise, Anne Maen_US
dc.date.accessioned2016-03-15T12:25:00Z
dc.date.available2016-03-15T12:25:00Z
dc.date.issued2013-07-16
dc.PublishedPLoS ONE 2013, 8(7)eng
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/1956/11648
dc.description.abstractBackground. Biomarkers to differentiate between active tuberculosis (TB) and latent TB infection (LTBI) and to monitor treatment responses are requested to complement TB diagnostics and control, particularly in patients with multi-drug resistant TB. We have studied soluble markers of the Toll-like-receptor 4 (TLR-4) pathway in various stages of TB disease and during anti-TB treatment. Methods. Plasma samples from patients with culture confirmed drug-sensitive TB (n = 19) were collected before and after 2, 8 and 24 weeks of efficient anti-TB treatment and in a LTBI group (n = 6). Soluble (s) CD14 and myeloid differentiation-2 (MD-2) were analyzed by the Enzyme-linked immunosorbent assay (ELISA). Lipopolysaccharide (LPS) was analyzed by the Limulus Amebocyte Lysate colorimetric assay. Nonparametric statistics were applied. Results. Plasma levels of sCD14 (p<0.001), MD-2 (p = 0.036) and LPS (p = 0.069) were elevated at baseline in patients with untreated active TB compared to the LTBI group. MD-2 concentrations decreased after 2 weeks of treatment (p = 0.011), while LPS levels decreased after 8 weeks (p = 0.005). In contrast, sCD14 levels increased after 2 weeks (p = 0.047) with a subsequent modest decrease throughout the treatment period. There was no significant difference in concentrations of any of these markers between patients with pulmonary and extrapulmonary TB or between patients with or without symptoms. Conclusion. Our data suggest that plasma levels of LPS, MD-2 and sCD14 can discriminate between active TB and LTBI. A decline in LPS and MD-2 concentrations was associated with response to anti-TB treatment. The clinical potential of these soluble TLR-4 pathway proteins needs to be further explored.en_US
dc.language.isoengeng
dc.publisherPLOS ONEeng
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.eng
dc.rights.urihttp://creativecommons.org/licenseseng
dc.titleSoluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment Responsesen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2015-11-20T11:10:55Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2013 Feruglio et al.
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0069896
dc.identifier.cristin1071582
dc.subject.nsiVDP::Medisinske Fag: 700en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Except where otherwise noted, this item's license is described as This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.